Core Foundations of the Shifting Regulatory Landscape The regulatory assessment of therapeutic biologics has evolved significantly from a framework centered […]
Strategic Frameworks for Bioanalytical Method Development for POC Therapeutics Establishing robust analytical assays for peptide-oligonucleotide conjugates requires highly specialized methodologies
Introduction: Biosimilar stability testing is not simply a regulatory checkbox — it is a rigorous scientific discipline that determines whether
Stability-Indicating Mass Spectrometry Methods for Biosimilars Read More »
Introduction: The generic pharmaceutical industry operates on razor-thin timelines and tighter regulatory scrutiny than ever before. For any manufacturer pursuing
Pre-ANDA Strategy: How to De-Risk Sameness Evaluation Early Read More »
What is the Scope of a CRO in IND-Enabling Studies for Peptide Oligonucleotide Conjugates? A specialized Contract Research Organization (CRO)
IND-Enabling Studies for POC Therapeutics: CRO Scope and Regulatory Deliverables Read More »
Deciphering the Biosimilar vs Generic Drug Differences in Modern Biopharma The biopharmaceutical industry has entered a transformative era in which
Introduction: Extractables and leachables in dexamethasone injectables represent one of the most critical — yet often underestimated — challenges in
Extractables and Leachables in Dexamethasone Injectables Read More »
Introduction: Bioanalytical method development for mRNA therapeutics is fundamentally different from conventional drug modalities — and getting it wrong at
Introduction: Impurity profiles in active ingredient sameness determinations are not a regulatory formality — they are a scientific proof of
Impurity Profiles and Their Role in Active Ingredient Sameness Read More »
Introduction: GMP manufacturing of peptide-oligonucleotide conjugates sits at the intersection of two highly complex chemistries — and getting it right
GMP Manufacturing of Peptide-Oligonucleotide Conjugates: What to Expect from a CRO Read More »
